Author

Simona Soverini

Assistant Professor, University of Bologna - Cited by 12,944 - hematology

Biography

Dr. Simona Soverini is from the Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Unit of Hematology, Bologna, Italy and has specialization in  Hematopoietic Stem Cells, Bone Marrow Transplantation, Fibroblast, Osteogenic differentiation.
Title
Cited by
Year
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013201
2448
2013
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European …
S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ...Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011201
678
2011
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
R Foa, A Vitale, M Vignetti, G Meloni, A Guarini, MS De Propris, L Elia, ...Blood, The Journal of the American Society of Hematology 118 (25), 6521-6528, 2011201
460
2011
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
T Hughes, G Saglio, S Branford, S Soverini, DW Kim, MC Müller, ...Journal of clinical oncology 27 (25), 4204, 2009200
378
2009
IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative …
G Martinelli, I Iacobucci, CT Storlazzi, M Vignetti, F Paoloni, D Cilloni, ...Journal of Clinical Oncology 27 (31), 5202-5207, 2009200
349
2009
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ...Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009200
284
2009
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute …
I Iacobucci, CT Storlazzi, D Cilloni, A Lonetti, E Ottaviani, S Soverini, ...Blood, The Journal of the American Society of Hematology 114 (10), 2159-2167, 2009200
256
2009
BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships
JS Khorashad, TW Kelley, P Szankasi, CC Mason, S Soverini, LT Adrian, ...Blood, The Journal of the American Society of Hematology 121 (3), 489-498, 2013201
248
2013
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with …
S Soverini, A Gnani, S Colarossi, F Castagnetti, E Abruzzese, S Paolini, ...Blood, The Journal of the American Society of Hematology 114 (10), 2168-2171, 2009200
197
2009
Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Baccarani, S Pileri, JL Steegmann, M Muller, S Soverini, M DreylingAnnals of oncology 23, vii72-vii77, 2012201
178
2012
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
S Soverini, S Branford, FE Nicolini, M Talpaz, MWN Deininger, ...Leukemia research 38 (1), 10-20, 2014201
176
2014
Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
S Soverini, C De Benedittis, K Machova Polakova, A Brouckova, D Horner, ...Blood, The Journal of the American Society of Hematology 122 (9), 1634-1648, 2013201
173
2013
Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
FE Nicolini, MJ Mauro, G Martinelli, DW Kim, S Soverini, MC Müller, ...Blood, The Journal of the American Society of Hematology 114 (26), 5271-5278, 2009200
139
2009
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
S Angelini, S Soverini, G Ravegnini, M Barnett, E Turrini, M Thornquist, ...haematologica 98 (2), 193, 2013201
119
2013
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or-intolerant patients with Philadelphia chromosome …
S Branford, DW Kim, S Soverini, A Haque, Y Shou, RC Woodman, ...Journal of clinical oncology 30 (35), 4323, 2012201
111
2012
Response definitions and european leukemianet management recommendations
M Baccarani, F Castagnetti, G Gugliotta, F Palandri, S SoveriniBest Practice & Research Clinical Haematology 22 (3), 331-341, 2009200
101
2009
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
S Soverini, A Vitale, A Poerio, A Gnani, S Colarossi, I Iacobucci, G Cimino, ...Haematologica 96 (4), 552, 2011201
101
2011
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia
I Iacobucci, N Iraci, M Messina, A Lonetti, S Chiaretti, E Valli, A Ferrari, ...PloS one 7 (7), e40934, 2012201
95
2012
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
F Castagnetti, F Palandri, M Amabile, N Testoni, S Luatti, S Soverini, ...Blood, The Journal of the American Society of Hematology 113 (15), 3428-3434, 2009200
92
2009
CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients
I Iacobucci, A Ferrari, A Lonetti, C Papayannidis, F Paoloni, S Trino, ...Clinical cancer research 17 (23), 7413-7423, 2011201
83
2011

Referred From: https://scholar.google.com/citations?user=JX9Ah_IAAAAJ&hl=en

Cited by
Citations 12944
h-index 52
i10-index 80
Recommended Journals
Open Access Journals